eLife (Oct 2014)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
- Young Seok Ju,
- Ludmil B Alexandrov,
- Moritz Gerstung,
- Inigo Martincorena,
- Serena Nik-Zainal,
- Manasa Ramakrishna,
- Helen R Davies,
- Elli Papaemmanuil,
- Gunes Gundem,
- Adam Shlien,
- Niccolo Bolli,
- Sam Behjati,
- Patrick S Tarpey,
- Jyoti Nangalia,
- Charles E Massie,
- Adam P Butler,
- Jon W Teague,
- George S Vassiliou,
- Anthony R Green,
- Ming-Qing Du,
- Ashwin Unnikrishnan,
- John E Pimanda,
- Bin Tean Teh,
- Nikhil Munshi,
- Mel Greaves,
- Paresh Vyas,
- Adel K El-Naggar,
- Tom Santarius,
- V Peter Collins,
- Richard Grundy,
- Jack A Taylor,
- D Neil Hayes,
- David Malkin,
- ICGC Breast Cancer Group,
- ICGC Chronic Myeloid Disorders Group,
- ICGC Prostate Cancer Group,
- Christopher S Foster,
- Anne Y Warren,
- Hayley C Whitaker,
- Daniel Brewer,
- Rosalind Eeles,
- Colin Cooper,
- David Neal,
- Tapio Visakorpi,
- William B Isaacs,
- G Steven Bova,
- Adrienne M Flanagan,
- P Andrew Futreal,
- Andy G Lynch,
- Patrick F Chinnery,
- Ultan McDermott,
- Michael R Stratton,
- Peter J Campbell
Affiliations
- Young Seok Ju
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Ludmil B Alexandrov
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Moritz Gerstung
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Inigo Martincorena
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Serena Nik-Zainal
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Manasa Ramakrishna
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Helen R Davies
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Elli Papaemmanuil
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Gunes Gundem
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Adam Shlien
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Niccolo Bolli
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Sam Behjati
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Patrick S Tarpey
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Jyoti Nangalia
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom
- Charles E Massie
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom
- Adam P Butler
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Jon W Teague
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- George S Vassiliou
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom
- Anthony R Green
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom
- Ming-Qing Du
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Ashwin Unnikrishnan
- Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia
- John E Pimanda
- Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia
- Bin Tean Teh
- Laboratory of Cancer Epigenome, National Cancer Centre, Singapore, Singapore; Duke-NUS Graduate Medical School, Singapore, Singapore
- Nikhil Munshi
- Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, United States
- Mel Greaves
- Institute of Cancer Research, Sutton, London, United Kingdom
- Paresh Vyas
- Weatherall Institute for Molecular Medicine, University of Oxford, Oxford, United Kingdom
- Adel K El-Naggar
- Department of Pathology, MD Anderson Cancer Center, Houston, United States
- Tom Santarius
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- V Peter Collins
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Richard Grundy
- Children's Brain Tumour Research Centre, University of Nottingham, Nottingham, United Kingdom
- Jack A Taylor
- National Institute of Environmental Health Sciences, National Institute of Health, Triangle, North Carolina, United States
- D Neil Hayes
- Department of Internal Medicine, University of North Carolina, Chapel Hill, United States
- David Malkin
- Hospital for Sick Children, University of Toronto, Toronto, Canada
- ICGC Breast Cancer Group
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- ICGC Chronic Myeloid Disorders Group
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- ICGC Prostate Cancer Group
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Institute of Cancer Research, Sutton, London, United Kingdom; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- Christopher S Foster
- Department of Molecular and Clinical Cancer Medicine, University of Liverpool, London, United Kingdom; HCA Pathology Laboratories, London, United Kingdom
- Anne Y Warren
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Hayley C Whitaker
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- Daniel Brewer
- Institute of Cancer Research, Sutton, London, United Kingdom; School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
- Rosalind Eeles
- Institute of Cancer Research, Sutton, London, United Kingdom
- Colin Cooper
- Institute of Cancer Research, Sutton, London, United Kingdom; School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
- David Neal
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- Tapio Visakorpi
- Institute of Biosciences and Medical Technology - BioMediTech and Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland
- William B Isaacs
- Department of Oncology, Johns Hopkins University, Baltimore, United States
- G Steven Bova
- Institute of Biosciences and Medical Technology - BioMediTech and Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland
- Adrienne M Flanagan
- Department of Histopathology, Royal National Orthopaedic Hospital, Middlesex, United Kingdom; University College London Cancer Institute, University College London, London, United Kingdom
- P Andrew Futreal
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Department of Genomic Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
- Andy G Lynch
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
- Patrick F Chinnery
- Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle-upon-tyne, United Kingdom
- Ultan McDermott
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Michael R Stratton
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Peter J Campbell
- Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Department of Haematology, University of Cambridge, Cambridge, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.02935
- Journal volume & issue
-
Vol. 3
Abstract
Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated mutations in mtDNA are unclear. In this study, we analyzed somatic alterations in mtDNA from 1675 tumors. We identified 1907 somatic substitutions, which exhibited dramatic replicative strand bias, predominantly C > T and A > G on the mitochondrial heavy strand. This strand-asymmetric signature differs from those found in nuclear cancer genomes but matches the inferred germline process shaping primate mtDNA sequence content. A number of mtDNA mutations showed considerable heterogeneity across tumor types. Missense mutations were selectively neutral and often gradually drifted towards homoplasmy over time. In contrast, mutations resulting in protein truncation undergo negative selection and were almost exclusively heteroplasmic. Our findings indicate that the endogenous mutational mechanism has far greater impact than any other external mutagens in mitochondria and is fundamentally linked to mtDNA replication.
Keywords